The latest biotech news

nanoparticles cancer thermotherapy UK2 1

News and Trends 25 Oct 2017

British Researchers Develop Clever Nanoparticles to Kill Cancer Cells

The University of Surrey has developed nanoparticles that heat up to kill cancer cells, but can then be controlled to protect healthy tissue. Research from the University of Surrey, published in Nanoscale, has been put forward as a new form of thermotherapy. Although it has been available for a long time, thermotherapy’s use is limited by […]

October 25, 2017 - 3 minutesmins - By Alex Dale

News and Trends 25 Oct 2017

The UK Recommends the use of GSK’s €594,000 Gene Therapy

Amidst uncertainty about the commercial future of expensive gene therapies, the UK’s NICE has declared GSK’s Strimvelis offers “value for money.” Approved by the EMA last year, Strimvelis is one of the most expensive drugs on the market. Although GSK is offering a money-back guarantee and payment through instalments, the price of the gene therapy, […]

October 25, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2017

Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval

Update (24/10/2017): Shingrix has been approved by the FDA and will cost $280 (€238) for the required two shots, which should be covered by most insurance plans. Originally published on 13/9/2017 An FDA panel voted 11-0 to support the approval of GSK’s new shingles vaccine based on “impressive” efficacy and safety results in a Phase III […]

October 24, 2017 - 3 minutesmins - By Alex Dale

News and Trends 24 Oct 2017

British Scientists Prove that it Takes Very Few Mutations to Cause Cancer

Researchers in the UK have analyzed over 7,500 tumors and estimate that a very low number of mutations is needed for cancer to develop. Researchers coming out of the prestigious Sanger Institute in Cambridge, UK has estimated that as few as 1 to 10 mutations are required to cause cancer. The study, published in Cell, was […]

October 24, 2017 - 2 minutesmins - By Alex Dale

News and Trends 24 Oct 2017

French Biotech‘s Bacterial Product is Ready to Enter the Anti-Aging Skincare Market

Montpellier-based Deinove has developed a bacterial anti-aging skincare product, which has shown its safety and healing capacity in studies so far. Deinove specializes in high-value compounds from rare bacteria, in particular, the Deinococcus genus. It has announced that it will launch its first cosmetic product into the anti-aging skincare market in 2018, which is based on a […]

October 24, 2017 - 2 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation

TiGenix’s candidate for a nasty Crohn’s disease complication received orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at a complication of Crohn’s disease – a nasty inflammatory condition affecting the intestine. Cx601 met efficacy and safety […]

October 23, 2017 - 2 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

The French biotech‘s hepatitis B vaccine has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus. Biotech veteran, Transgene, specializes in viral-based immunotherapies for cancers and infectious diseases. One of its targets, hepatitis B, is a potentially fatal liver infection caused by the hepatitis B virus (HBV). Today, it has […]

October 23, 2017 - 2 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments

ADC Therapeutics has received massive private funding to progress two of its lead candidates for cancer through clinical trials. ADC Therapeutics, based in Lausanne, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for the treatment of cancer. The technology uses the specificity of antibodies to deliver a therapeutic agent to target cells only. The biotech has […]

October 23, 2017 - 3 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval

DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to meet a primary endpoint in Phase III. Last Friday, DBV Technologies released the results of a Phase III trial that was key to the approval of a treatment to reduce peanut allergy in children. After 12 months, 35% of children […]

October 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Oct 2017

A Peptide Reduces Bleeding in Surgery in Phase II Trials

Ergomed has announced positive results in Phase II with PeproStat, a peptide solution to stop bleeding during surgery faster. In a Phase II study that recruited 169 patients across 16 European hospitals, London-based Ergomed has demonstrated that itspipeline’s lead candidate, PeproStat, can reduce the time to achieve hemostasis, that is, for the bleeding to stop, […]

October 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Oct 2017

Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene

The PTEN gene controls cell growth and behavior, with its loss implicated in cancer. AstraZeneca and Babraham have collaborated to improve our understanding of how this happens. The Babraham Institute, Cambridge, UK and AstraZeneca have unveiled research that helps us to better understand a key cancer gene, PTEN – reportedly the second most altered gene in cancers. […]

October 20, 2017 - 2 minutesmins - By Alex Dale

News and Trends 19 Oct 2017

Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech

Inbiomotion has published the results of a Phase III study looking at its MAFTest to personalized approaches to the disease. Inbiomotion, based in Barcelona’s biotech hub, works on a highly selective biomarker for breast cancer. A Phase III study demonstrated that breast cancer patients that would benefit from zoledronic acid therapy can be selected, helping clinicians offer […]

October 19, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

British Researchers Develop Clever Nanoparticles to Kill Cancer Cells

The UK Recommends the use of GSK’s €594,000 Gene Therapy

Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval

British Scientists Prove that it Takes Very Few Mutations to Cause Cancer

French Biotech‘s Bacterial Product is Ready to Enter the Anti-Aging Skincare Market

FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments

Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval

A Peptide Reduces Bleeding in Surgery in Phase II Trials

Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene

Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!